These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29226311)

  • 1. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
    Cruz M; Reinert T; Cristofanilli M
    Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer.
    Malumbres M
    Cancer Cell; 2016 Mar; 29(3):243-244. PubMed ID: 26977873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
    Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
    Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
    Migliaccio I; Bonechi M; McCartney A; Guarducci C; Benelli M; Biganzoli L; Di Leo A; Malorni L
    Cancer Treat Rev; 2021 Feb; 93():102136. PubMed ID: 33360919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Weiss J; Afghahi A; Shagisultanova E; Diamond JR
    Oncology (Williston Park); 2018 Oct; 32(10):513-5. PubMed ID: 30334242
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
    Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
    Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.
    Scheidemann ER; Shajahan-Haq AN
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
    Mancuso MR; Massarweh SA
    Curr Probl Cancer; 2016; 40(2-4):95-105. PubMed ID: 27839747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.